Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 10 of 13 for:    selinexor | Myeloma

Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02343042
Recruitment Status : Recruiting
First Posted : January 21, 2015
Last Update Posted : April 17, 2020
Sponsor:
Information provided by (Responsible Party):
Karyopharm Therapeutics Inc

Brief Summary:

This study will independently assess the efficacy and safety of 8 combination therapies in 9 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are:

  • Arm 1: Selinexor + dexamethasone + pomalidomide (SPd)
  • Arm 2: Selinexor + dexamethasone + bortezomib (SVd); enrollment complete
  • Arm 3: Selinexor + dexamethasone + lenalidomide (SRd) in RRMM; enrollment complete
  • Arm 4: Selinexor + dexamethasone + pomalidomide + bortezomib (SPVd)
  • Arm 5: Selinexor + dexamethasone + daratumumab (SDd); enrollment complete
  • Arm 6: Selinexor + dexamethasone + carfilzomib (SKd)
  • Arm 7: Selinexor + dexamethasone + lenalidomide (SRd) in NDMM
  • Arm 8: Selinexor + dexamethasone + ixazomib (SNd)
  • Arm 9: Selinexor + dexamethasone + pomalidomide + elotuzumab (SPEd)

Selinexor pharmacokinetics:

  • PK Run-in (Days 1-14):

Starting in protocol version 8.0, patients enrolled to any arm in the Dose Escalation Phase (i.e., Arm 4 SPVd, Arm 6 SKd, Arm 8 SNd, Arm 9 SPEd) will also first be enrolled to a pharmacokinetics (PK) Run-in period until 9 patients have been enrolled to this period to evaluate the PK of selinexor before and after co-administration with a strong CYP3A4 inhibitor.


Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Selinexor Drug: Dexamethasone Drug: Lenalidomide Drug: Pomalidomide Drug: Bortezomib Drug: Daratumumab Drug: Carfilzomib Drug: Ixazomib Drug: Elotuzumab Drug: Clarithromycin Phase 1 Phase 2

Detailed Description:

This is a multi-center, open-label, clinical study with Dose Escalation (Phase 1) and Expansion (Phase 2) to independently assess the MTD, efficacy , and safety of 8 combination therapies in 9 arms in patients with RRMM and NDMM. Patients will be assigned to treatment arms based on their diagnoses and treatment histories. For 9 patients, a PK Run-in period will precede Cycle 1 (DLT evaluation) to assess selinexor PK when co-administered with a strong CYP3A4 inhibitor. In the Dose Escalation Phase (Phase 1): (a) in Arm 1 (SPd), Arm 2 (SVd), and Arm 3 (SRd in RRMM), patients will be randomized to either QW or BIW selinexor dosing cohorts; (b) in Arm 5 (SDd), patients will be sequentially assigned in blocks of 3 to either QW or BIW selinexor dosing; (c) in Arm 4 (SPVd), Arm 6 (SKd), Arm 7 (Srd in NDMM), Arm 8 (SNd), and Arm 9 (SPEd), patients will be assigned to QW selinexor dosing.

Starting in protocol version 8.0, patients enrolled to the Dose Escalation Phase of Arm 4 (SPVd), Arm 6 (SKd), Arm 8 (SNd), and Arm 9 (SPEd) will first be enrolled to a 14-day PK Run-in period (selinexor +/- clarithromycin) until 9 patients have been enrolled. During this 14-day PK Run-in period, selinexor 40 mg will be administered alone on Day 1, clarithromycin 500 mg twice daily (BID) will be administered on Days 2-8, and selinexor 40 mg will again be administered on Day 8 with the morning clarithromycin dose. Blood samples for PK analysis will be collected pre-dose and 1 (± 10 min), 1.5 (± 10 min), 2 (± 10 min), 3 (± 10 min), 4 (± 10 min), 5 (± 10 min), 6 (± 10 min), 8 (± 10 min), and 24 h (± 30 min) hours after selinexor is dosed on Day 1 (without clarithromycin) and Day 8 (with clarithromycin). Patients will then proceed to the DLT evaluation period that will begin after the completion of the 14-day PK Run-in period; this day will be designated as Cycle 1 Day 1 (C1D1) in the Dose Escalation Phase.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 437 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
Actual Study Start Date : October 2015
Estimated Primary Completion Date : May 2020
Estimated Study Completion Date : May 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: 1: Selinexor, Low-dose Dexamethasone & Pomalidomide (SPd)

Each cycle is 28 days

Cohort 1.1: SEL 60/80/100 mg PO once weekly DEX 40 mg PO once weekly POM 2/3/4 mg PO Days 1-21

Cohort 1.2: SEL 40/60/80 mg PO twice weekly DEX 20 mg PO twice weekly POM 3/4 mg PO Days 1-21

Drug: Selinexor
Tablets
Other Names:
  • KPT-330
  • XPOVIO®

Drug: Dexamethasone
Oral tablets in a multi-dose vial
Other Name: Decadron®

Drug: Pomalidomide
Oral tablets
Other Name: Pomalyst®

Experimental: 2: Selinexor, Low-dose Dexamethasone & Bortezomib (SVd)

One cycle is either 21 or 35 days (depending on bortezomib dosing schedule)

Cohort 2.1: SEL 60/80/100 mg PO once weekly DEX 40 mg PO once weekly BOR 1.3 mg/m² subcutaneous (SC) once weekly

Cohort 2.2: SEL 40/60/80 mg PO twice weekly DEX 20 mg PO twice weekly BOR 1.3 mg/m² subcutaneous (SC) once weekly

Drug: Selinexor
Tablets
Other Names:
  • KPT-330
  • XPOVIO®

Drug: Dexamethasone
Oral tablets in a multi-dose vial
Other Name: Decadron®

Drug: Bortezomib
Subcutaneous Injection (single use vial)
Other Name: Velcade®

Experimental: 3: Selinexor, Low-dose DEX, & Lenalidomide (SRd) in RR MM

Each cycle is 28 days

Cohort 3.1: SEL 40/60/80/100 mg PO once weekly DEX 40 mg PO once weekly LEN 15/25 mg PO Days 1-21

Cohort 3.2: SEL 40/60/80 mg PO twice weekly DEX 20 mg PO twice weekly LEN 15/25 mg PO Days 1-21

Drug: Selinexor
Tablets
Other Names:
  • KPT-330
  • XPOVIO®

Drug: Dexamethasone
Oral tablets in a multi-dose vial
Other Name: Decadron®

Drug: Lenalidomide
Oral capsule
Other Name: Revlimid®

Experimental: 4:Selinexor,Low-dose dexamethasone,Pomalidomide,Velcade (SPVd)

PK Run-in Period: Selinexor & Clarithromycin:

  • For the first 9 patients enrolled into this dose escalation arm
  • 14 day run-in period after which patients will proceed to Dose-Escalation Phase C1D1

Selinexor 40 mg will be dosed on Day 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.

PK samples will be collected on Day 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.

Dose-escalation Phase:

  • All patients enrolled into this Arm
  • Each cycle is 28 days.

Cohort 4.1:

SEL 20/40/60 mg PO once weekly DEX 40 mg PO once weekly POM 2/4 mg PO Days 1-21 BOR 1.3 mg/m² subcutaneous (SC) once weekly

Drug: Selinexor
Tablets
Other Names:
  • KPT-330
  • XPOVIO®

Drug: Dexamethasone
Oral tablets in a multi-dose vial
Other Name: Decadron®

Drug: Pomalidomide
Oral tablets
Other Name: Pomalyst®

Drug: Bortezomib
Subcutaneous Injection (single use vial)
Other Name: Velcade®

Drug: Clarithromycin
Tablets
Other Name: Biaxin

Experimental: 5: Selinexor, Low-dose dexamethasone, & Daratumumab (SDd)

Each cycle is 28 days

Cohort 5.1:

SEL 80/100 mg PO once weekly DEX 40 mg once weekly (IV or PO) DARA: 16 mg/kg IV infusion Cycle 1-2: Once weekly Cycle 3-6: Every other week Cycle 6 and greater: Once a month

Cohort 5.2:

SEL: 60 mg PO twice weekly DEX: 40 mg weekly (IV or PO) DARA: 16 mg/kg IV infusion Cycle 1-2: Once. weekly Cycle 3-6: Every other week Cycle 6 and greater: Once a month

Drug: Selinexor
Tablets
Other Names:
  • KPT-330
  • XPOVIO®

Drug: Dexamethasone
Oral tablets in a multi-dose vial
Other Name: Decadron®

Drug: Daratumumab
Intravenous Infusion
Other Name: Darzalex®

Experimental: 6: Selinexor, Low-dose dexamethasone, & Carfilzomib (SKd)

PK Run-in Period: Selinexor & Clarithromycin:

  • For the first 9 patients enrolled into this dose escalation arm
  • 14 day run-in period after which patient will proceed to Dose-Escalation Phase C1D1

Selinexor 40 mg will be dosed on Day 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.

PK samples will be collected on Day 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.

Dose-Escalation Phase:

  • All patients enrolled into this Arm
  • Each cycle is 28 days

Cohort 6.1:

SEL 60/80/100 mg PO once weekly on days 1, 8, 15, and 22 DEX 40 mg IV or PO once weekly CAR 56 or 70 mg/m² IV infusion once weekly on days 1, 8, 15, and 22.

Cohort 6.2:

SEL 60/80/100 mg PO once weekly on day 1, 8, and 15. DEX 40 mg IV or PO once weekly CAR 56 or 70 mg/m² IV infusion once weekly on day 1, 8, and 15.

Drug: Selinexor
Tablets
Other Names:
  • KPT-330
  • XPOVIO®

Drug: Dexamethasone
Oral tablets in a multi-dose vial
Other Name: Decadron®

Drug: Carfilzomib
Intravenous Infusion
Other Name: Kyprolis®

Drug: Clarithromycin
Tablets
Other Name: Biaxin

Experimental: 7: Selinexor,Low-dose DEX & Lenalidomide (SRd) in NDMM

Each cycle is 28 days

Cohort 7.1:

SEL 40/60/80 mg PO once weekly DEX 40 mg PO once weekly LEN 25 mg PO Days 1-21

Drug: Selinexor
Tablets
Other Names:
  • KPT-330
  • XPOVIO®

Drug: Dexamethasone
Oral tablets in a multi-dose vial
Other Name: Decadron®

Drug: Lenalidomide
Oral capsule
Other Name: Revlimid®

Experimental: 8: Selinexor, Low-dose dexamethasone, & Ixazomib (SNd)

PK Run-in Period: Selinexor & Clarithromycin:

  • For the first 9 patients enrolled into this dose escalation arm
  • 14 day run-in period after which patient will proceed to Dose-Escalation Phase C1D1

Selinexor 40 mg will be dosed on Day 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.

PK samples will be collected on Day 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.

Dose-Escalation Phase:

  • All patients enrolled into this Arm
  • Each cycle is 28 days

Cohort 8.1:

SEL 60/80/100 mg PO once weekly DEX 20 mg PO twice weekly IXA 3/4 mg PO Days once weekly

Drug: Selinexor
Tablets
Other Names:
  • KPT-330
  • XPOVIO®

Drug: Dexamethasone
Oral tablets in a multi-dose vial
Other Name: Decadron®

Drug: Ixazomib
Oral capsule
Other Name: Ninlaro®

Drug: Clarithromycin
Tablets
Other Name: Biaxin

Experimental: 9: Selinexor, Low-dose DEX, Pomalidomide & Elotuzumab

PK Run-in Period: Selinexor & Clarithromycin:

  • For the first 9 patients enrolled into this dose escalation arm
  • 14 day run-in period after which patient will proceed to Dose-Escalation Phase C1D1

Selinexor 40 mg will be dosed on Day 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.

PK samples will be collected on Day 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.

Dose-Escalation Phase:

  • All patients enrolled into this Arm
  • Each cycle is 28 days

Cohort 9.1:

SEL 40/60/80 mg PO once weekly DEX 28/20 mg PO twice weekly POM 2/4 mg PO Days 1-21 ELO 10 mg/kg IV will be given once weekly on Days 1,8, 15 and 22 of Cycles 1-2. Starting on Cycle 3 and continuing for future cycles, elotuzumab will be dosed at 20 mg/kg on Day 1 of each cycle only.

Drug: Selinexor
Tablets
Other Names:
  • KPT-330
  • XPOVIO®

Drug: Dexamethasone
Oral tablets in a multi-dose vial
Other Name: Decadron®

Drug: Pomalidomide
Oral tablets
Other Name: Pomalyst®

Drug: Elotuzumab
Intravenous Infusion
Other Name: Empliciti®

Drug: Clarithromycin
Tablets
Other Name: Biaxin




Primary Outcome Measures :
  1. Phase 1 (Dose-escalation) [ Time Frame: 12 months ]
    Maximum tolerated dose (MTD) for once weekly (QW) and twice weekly (BIW) selinexor dose cohorts in the 9 Arms being evaluated

  2. Phase 1 (Dose-escalation) [ Time Frame: 12 months ]
    Recommended Phase-2 dose (RP2D) for each Arm

  3. Phase 1 (Dose-escalation) [ Time Frame: 14 days ]
    Maximum plasma concentration (Cmax) of selinexor over a dosing interval when given with and without clarithromycin

  4. Phase 1 (Dose-escalation) [ Time Frame: 14 days ]
    Total exposure of selinexor in the blood (AUC0-last) from the time of dosing to the last measurable concentration collected when given with and without clarithromycin

  5. Phase 2 (Expansion) [ Time Frame: 12 months ]
    Overall response rate (ORR) for each Arm independently. ORR to include stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR), according to the International Myeloma Working Group (IMWG) criteria.

  6. Phase 2 (Expansion) [ Time Frame: 12 months ]
    Duration of response (DOR) for each Arm

  7. Phase 2 (Expansion) [ Time Frame: 12 months ]
    Clinical benefit rate (CBR), defined as ORR plus minimal response (MR) for each Arm



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written informed consent in accordance with federal, local, and institutional guidelines.
  2. Age ≥ 18 years at the time of informed consent.
  3. Histologically confirmed diagnosis with measurable disease for relapsed/refractory myeloma.
  4. Symptomatic MM for NDMM needing therapy, based on IMWG guidelines.
  5. Patients must have measurable disease as defined by at least one of the following:

    1. Serum M-protein ≥ 0.5 g/dL by serum protein electrophoresis (SPEP) or, for IgA myeloma, by quantitative IgA
    2. Urinary M-protein excretion at least 200 mg/24 hours
    3. Serum FLC ≥ 100 mg/L, provided that FLC ratio is abnormal
    4. If SPEP is felt to be unreliable for routine M-protein measurement (e.g., for IgA MM), then quantitative Ig levels by nephelometry or turbidometry are acceptable
  6. Any non-hematological toxicities (except for peripheral neuropathy as described in exclusion criterion #22) that patients had from treatments in previous clinical studies must have resolved to ≤ Grade 2 by Cycle 1 Day 1.
  7. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2.
  8. Adequate hepatic function within 28 days prior to C1D1:

    • For SPd, SRd, and SPEd: Total bilirubin < 2x upper limit of normal (ULN) (except patients with Gilbert's syndrome [hereditary indirect hyperbilirubinemia] who must have a total bilirubin of ≤ 3x ULN) and both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5x ULN
    • For SVd, SPVd, SDd, and SNd: Total bilirubin of < 1.5x ULN (except patients with Gilbert's syndrome [hereditary indirect hyperbilirubinemia] who must have a total bilirubin of ≤ 3x ULN) and both AST and ALT < 2.0x ULN
    • For SKd: Total bilirubin < 2x ULN (except patients with Gilbert's syndrome [hereditary indirect hyperbilirubinemia] who must have a total bilirubin of ≤ 3x ULN) and both AST and ALT < 3.0x ULN
  9. Adequate renal function within 28 days prior to C1D1. Estimated creatinine clearance (CrCl) calculated using the formula of Cockroft and Gault (1976):

    • ≥ 20 mL/min for SVd, SDd, and SKd arms
    • ≥ 30 mL/min for SNd arm
    • ≥ 45 mL/min for SPd, SPVd, and SPEd arms
    • > 60 mL/min for SRd arm
  10. Adequate hematopoietic function within 28 days prior to C1D1: total white blood cell (WBC) count ≥ 1,500/mm³, ANC ≥ 1,000/mm³, hemoglobin (Hb) ≥ 8.0 g/dL, and platelet count ≥ 150,000/mm³.
  11. Female patients of childbearing potential must have a negative serum pregnancy test at Screening. Female patients of childbearing potential and fertile male patients who are sexually active with a female of childbearing potential must use highly effective methods of contraception throughout the study and for 1 week following the last dose of study treatment.

    SPd (Arm 1) Only:

  12. Relapsed and refractory MM with:

    1. Documented evidence of progressive disease (PD) after achieving at least stable disease (SD) for ≥ 1 cycle during a previous MM regimen (i.e., relapsed MM)
    2. ≤ 25% response (i.e., patients never achieved ≥ MR) or PD during or within 60 days from the end of the most recent MM regimen (i.e., refractory MM)
    3. Previously undergone ≥ 2 cycles of lenalidomide and a PI (in separate therapeutic regimens [not for maintenance] or in combination)
    4. In the expansion arm at RP2D, patients must not be pomalidomide refractory

    SVd (Arm 2) Only:

  13. Relapsed or refractory MM with:

    1. Documented evidence of relapse after ≥ 1 previous line of therapy
    2. Not refractory to bortezomib in their most recent line of therapy

    SRd in RRMM (Arm 3) Only:

  14. Patients who received ≥ 1 prior therapeutic regimen (prior lenalidomide is allowed as long as patient's MM was not refractory to prior lenalidomide; patients whose MM was refractory to lenalidomide maintenance regimens will be allowed in this cohort).

    SPVd (Arm 4) Only:

  15. Patients who received 1- 3 prior lines of therapy, including ≥ 2 cycles of lenalidomide and have demonstrated disease progression on their last therapy (may include prior bortezomib, as long as the patient's MM was not refractory to bortezomib therapy), but patients must be pomalidomide-naïve in the Dose Expansion at RP2D (Cohort 4.3 ONLY).

    SDd (Arm 5) Only:

  16. Patients who received ≥ 3 prior lines of therapy, including a PI and an IMiD, or patients with MM refractory to both a PI and an IMiD.
  17. Patients must not have received prior anti-CD38 monoclonal antibodies (Cohort 5.3 ONLY - Dose Expansion at RP2D).

    SKd (Arm 6) Only:

  18. Patients may have received prior PIs; however, their MM must NOT be refractory to carfilzomib.

    SRd in NDMM (Arm 7) Only:

  19. Patients must have symptomatic myeloma per IMWG guidelines with either CRAB criteria or myeloma-defining events and need systemic therapy. No prior systemic therapy for NDMM is permitted other than pulse dose dexamethasone (maximum dose of 160 mg) or corticosteroid equivalent.

    SNd (Arm 8) Only:

  20. Patients must have MM that relapsed after 1 - 3 prior lines of therapy (may not include those with MM refractory to bortezomib or carfilzomib and patients must be ixazomib-naïve).

    SPEd (Arm 9) Only:

  21. Patients who received ≥ 2 prior therapies, including lenalidomide and a PI (in separate or the same regimens), but patients must be pomalidomide-naïve and elotuzumab-naïve in the Dose Expansion at RP2D (Cohort 9.3 ONLY).

Exclusion Criteria:

Patients meeting any of the following exclusion criteria are not eligible to enroll in this study:

  1. Smoldering MM
  2. MM that does not express M-protein or FLC (i.e., non-secretory MM is excluded), and quantitative immunoglobulin levels cannot be used instead
  3. Documented active systemic amyloid light chain amyloidosis
  4. Active plasma cell leukemia
  5. Red Blood Cell (RBC) and platelet transfusions and blood growth factors within 14 days of C1D1.
  6. Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤ 2 weeks prior to C1D1, and radio-immunotherapy within 6 weeks prior to C1D1. Patients on long-term glucocorticoids during Screening do not require a washout period. Prior radiation is permitted for treatment of fractures or to prevent fractures as well as for pain management
  7. Patients with history of SCC with residual paraplegia (Dose Escalation Phase only).
  8. Treatment with an investigational anti-cancer therapy within 3 weeks prior to C1D1
  9. Prior autologous stem cell transplantation < 1 month, or allogeneic stem cell transplantation < 3 months prior to C1D1
  10. Active graft versus host disease after allogeneic stem cell transplantation
  11. Life expectancy < 3 months
  12. Major surgery within 4 weeks prior to C1D1
  13. Active, unstable cardiovascular function:

    1. Symptomatic ischemia, or
    2. Uncontrolled clinically-significant conduction abnormalities (e.g., patients with ventricular tachycardia on antiarrhythmics are excluded; patients with 1st degree atrioventricular (AV) block or asymptomatic left anterior fascicular block/right bundle branch block (LAFB/RBBB) will not be excluded), or
    3. Congestive heart failure (CHF) of New York Heart Association (NYHA) Class ≥ 3, or
    4. Myocardial infarction (MI) within 3 months prior to C1D1
    5. Ejection fraction (EF) < 50% at Screening
  14. Uncontrolled active hypertension
  15. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose
  16. Known active hepatitis A, B or C
  17. Known HIV infection or HIV seropositivity
  18. Any active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of study treatment
  19. Currently pregnant or breastfeeding
  20. A serious psychiatric or medical condition which, in the opinion of the Investigator, could interfere with treatment
  21. Hypersensitivity to any of the treatments for the Arm in which the patient is enrolled
  22. Prior exposure to a SINE compound, including selinexor

    In the SVd Arm (Arm 2), SPVd (Arm 4), and SNd Arm (Arm 8) only:

  23. Prior history of neuropathy Grade > 2, or Grade ≥ 2 neuropathy with pain at screening (within 28 days prior to C1D1).

    Patients who are eligible for the selinexor PK Run-in only:

  24. Treatment with moderate or strong inhibitors/inducers of CYP3A within 7 days prior to Day 1 of the PK Run-in period
  25. Not able to receive a strong CYP3A4 inhibitor due to concomitant medications

    SKd Arm only:

  26. HBs Ag + plus HBc Ab + even though no active HBV hepatitis. If HBs Ag - plus HBc Ab +, treating physician needs to contact the medical monitor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02343042


Contacts
Layout table for location contacts
Contact: Michael Kauffman, MD, PhD mkauffman@karyopharm.com
Contact: Sharon Shacham, PhD SShacham@karyopharm.com

Locations
Show Show 19 study locations
Sponsors and Collaborators
Karyopharm Therapeutics Inc
Investigators
Layout table for investigator information
Study Director: Michael Kauffman, MD, Ph.D Karyopharm Therapeutics Inc

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Karyopharm Therapeutics Inc
ClinicalTrials.gov Identifier: NCT02343042    
Other Study ID Numbers: KCP-330-017
First Posted: January 21, 2015    Key Record Dates
Last Update Posted: April 17, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Keywords provided by Karyopharm Therapeutics Inc:
Selinexor
Multiple Myeloma
KCP-330
STOMP
Relapsed/Refractory
Dexamethasone
Pomalidomide
Bortezomib
Karyopharm
Lenalidomide
Daratumumab
Newly Diagnosed
Carfilzomib
Ixazomib
Elotuzumab
Clarithromycin
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Clarithromycin
Dexamethasone
Lenalidomide
Bortezomib
Pomalidomide
Daratumumab
Ixazomib
Elotuzumab
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones